Skip to main content
Top
Published in: Journal of Cancer Education 2/2018

01-04-2018

Understanding Breast Cancer Survivors’ Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence

Authors: Alejandra Hurtado-de-Mendoza, Roxanne E. Jensen, Yvonne Jennings, Vanessa B. Sheppard

Published in: Journal of Cancer Education | Issue 2/2018

Login to get access

Abstract

Adjuvant hormonal therapy is recommended for women with hormone receptor (HR)-positive breast cancer. Though critical, many patients are non-adherent to this therapy. Few scales have been developed to specifically address beliefs about adjuvant hormonal therapy. This study explores the clarity and relevance of the Beliefs about Medicine Questionnaire (BMQ) in the context of adherence behaviors to hormonal therapy in Black and White breast cancer survivors. We recruited women diagnosed with HR-positive cancer from the Washington, DC, area. An interviewer administered a standardized survey and conducted a cognitive interview. Participants rated the BMQ across three areas: relevance, difficulty, and clarity. We coded whether the comments identified item level issues: limited applicability, unclear reference, unclear perspective, or wording or tone. In-depth interviews were conducted with women who prematurely discontinued hormone therapy. The sample (n = 30) was equally split between Black and White survivors. On average, women were 57.9 years old (SD = 9.0). Overall 77% rated scale as relevant. Cognitive interviews revealed areas of perceived limited acceptability such as the notion of becoming too dependent or the notion of becoming worse if not taking the medication. Women who discontinued hormonal therapy (n = 2) felt ambivalent towards hormonal therapy as they reported having both positive and negative beliefs about the medication. Our study findings suggest new areas for further research and instrument development to accurately measure self-reported beliefs about hormonal therapy by HR-positive breast cancer survivors.
Literature
1.
go back to reference Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. doi:10.1016/S0140-6736(12)61963-1 Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. doi:10.​1016/​S0140-6736(12)61963-1
2.
go back to reference Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-1132-4 Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-1132-4
3.
go back to reference Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. doi:10.1200/JCO.2005.04.5799 Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. doi:10.​1200/​JCO.​2005.​04.​5799
4.
go back to reference Horne, R. and J. Weinman (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res Horne, R. and J. Weinman (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res
5.
go back to reference Silliman, R. A., E. Guadagnoli, W. Rakowski, M. B. Landrum, T. L. Lash, R. Wolf, A. Fink, P. A. Ganz, J. Gurwitz, C. Borbas and V. Mor (2002) Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology Silliman, R. A., E. Guadagnoli, W. Rakowski, M. B. Landrum, T. L. Lash, R. Wolf, A. Fink, P. A. Ganz, J. Gurwitz, C. Borbas and V. Mor (2002) Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology
6.
go back to reference Lash, T. L., M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman (2006) Adherence to tamoxifen over the five-year course. Breast cancer research and treatment Lash, T. L., M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman (2006) Adherence to tamoxifen over the five-year course. Breast cancer research and treatment
7.
go back to reference Fink, A. K., J. Gurwitz, W. Rakowski, E. Guadagnoli and R. A. Silliman (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Fink, A. K., J. Gurwitz, W. Rakowski, E. Guadagnoli and R. A. Silliman (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
8.
go back to reference Bickell, N. A., J. Weidmann, K. Fei, J. J. Lin and H. Leventhal. (2009) Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology Bickell, N. A., J. Weidmann, K. Fei, J. J. Lin and H. Leventhal. (2009) Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology
10.
go back to reference Collins, D. (2003) Pretesting survey instruments: an overview of cognitive methods. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation Collins, D. (2003) Pretesting survey instruments: an overview of cognitive methods. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation
11.
go back to reference Daugherty, Sarah, Lauren Harris-Kojetin, Claudia Squire, Elizabeth Jaël and L. Harris-Kojetin (2001) Maximizing the quality of cognitive interviewing data: An exploration of three approaches and their informational contributions Daugherty, Sarah, Lauren Harris-Kojetin, Claudia Squire, Elizabeth Jaël and L. Harris-Kojetin (2001) Maximizing the quality of cognitive interviewing data: An exploration of three approaches and their informational contributions
12.
go back to reference Jobe, Jared B. (2003) Cognitive psychology and self-reports: models and methods. Quality of Life Research Jobe, Jared B. (2003) Cognitive psychology and self-reports: models and methods. Quality of Life Research
13.
go back to reference Knafl K, Deatrick J, Gallo A, Holcombe G, Bakitas M, Dixon J, Grey M (2007) The analysis and interpretation of cognitive interviews for instrument development. Research in nursing & health. doi:10.1002/nur.20195 Knafl K, Deatrick J, Gallo A, Holcombe G, Bakitas M, Dixon J, Grey M (2007) The analysis and interpretation of cognitive interviews for instrument development. Research in nursing & health. doi:10.​1002/​nur.​20195
14.
go back to reference Pellegrini, I., A. Sarradon-Eck, P. B. Soussan, A. C. Lacour, R. Largillier, A. Tallet, C. Tarpin and C. Julian-Reynier (2010) Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psycho-oncology Pellegrini, I., A. Sarradon-Eck, P. B. Soussan, A. C. Lacour, R. Largillier, A. Tallet, C. Tarpin and C. Julian-Reynier (2010) Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psycho-oncology
15.
go back to reference Conner, M., R. Povey, P. Sparks, R. James and R. Shepherd. (2003) Moderating role of attitudinal ambivalence within the theory of planned behaviour. The British journal of social psychology / the British Psychological Society. doi: 10.1348/014466603763276135 Conner, M., R. Povey, P. Sparks, R. James and R. Shepherd. (2003) Moderating role of attitudinal ambivalence within the theory of planned behaviour. The British journal of social psychology / the British Psychological Society. doi: 10.​1348/​0144666037632761​35
Metadata
Title
Understanding Breast Cancer Survivors’ Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence
Authors
Alejandra Hurtado-de-Mendoza
Roxanne E. Jensen
Yvonne Jennings
Vanessa B. Sheppard
Publication date
01-04-2018
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 2/2018
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-017-1180-0

Other articles of this Issue 2/2018

Journal of Cancer Education 2/2018 Go to the issue

EDITORIAL

On Writing

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine